Editorial

Charles Kennedy¹

Published online: 4 January 2021

© Springer Nature B.V. 2021

As you may have seen from the announcements on the journal's website, Tim Arnett, Kazuhide Inoue and Jean-Pierre Timmermans have all recently stepped down as Associate Editors of the journal and once again I would like to thank them for their excellent service over many years. Rodrigo Cunha is also stepping down and I thank him too for his efforts. Isabel Orriss, Schuichi Koizumi and Brian Gulbransen were announced online as their replacements and now I am delighted to tell you that Silvia Deaglio, Serena Longhi and Karen Dwyer have all also agreed to become Associate Editors. In addition, Elena Adinolfi and Stefania Ceruti have agreed to join the Editorial Board. Our new members are all excellent research scientists who have made significant contributions to the field of purinergic receptors and signalling and I look forward to working with them.

Finally, it was recently agreed with Springer Nature that I will formally succeed Geoff Burnstock as Editor-in-Chief of *Purinergic Signalling* on January 1, 2021, and I look forward to working with you all in the coming years.

Compliance with ethical standards

Conflicts of interest Charles Kennedy declares that he has no conflict of interest.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Charles Kennedy
c.kennedy@strath.ac.uk

¹ Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde, 161 Cathedral Street,
Glasgow, Scotland G4 0RE, UK